|
1.
|
|
7 p, 716.5 KB |
Current professional standing of young medical oncologists in Spain : a nationwide survey by the Spanish Society of Medical Oncology + MIR section
/
Martinez, Domingo Antonio Sanchez (IMIB, Virgen de La Arrixaca University Hospital. Department of Medical Oncology) ;
Quilez-Cutillas, Aliica (Department of Medical Oncology, Can Misses Hospital, Área de Salud de Ibiza y Formentera (ASEF), Ibiza, Illes Balears Spain) ;
Jimenez-Labaig, Pablo (Cruces University Hospital. Department of Medical Oncology) ;
Sesma, Andrea (Lozano Blesa University Clinical Hospital. Department of Medical Oncology) ;
Tarazona, Noelia (Instituto de Salud Carlos III, CIBERONC) ;
Pacheco-Barcia, Vilma (Torrejón University Hospital. Department of Medical Oncology) ;
Obispo, Berta (Hospital Universitario Infanta Leonor) ;
Paez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Quintanar, Teresa (Hospital General Universitario de Elche) ;
Sanchez-Canovas, Manuel (Morales Meseguer University General Hospital. Department of Hematology and Medical Oncology) ;
Montes, Ana Fernandez (University Hospital Complex of Ourense (CHUO). Department of Medical Oncology) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Rodriguez-Lescure, Alvaro (Elche University General Hospital. Department of Medical Oncology) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
There is a lack of knowledge about the career paths and employment situation of young medical oncologists. The aim of our study was to evaluate the current professional standing of these professionals in Spain. [...]
2022 -  10.1007/s12094-022-02989-3
Clinical & Translational Oncology, november 2022, p. 1-7
|
|
|
2.
|
|
6 p, 348.3 KB |
Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients
/
Martinez, Pablo (Vall d'Hebron Institut d'Oncologia) ;
Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ;
Castellvi, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
Tallada, Natalia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Murtra-Garrell, Nuria (Vall d'Hebron Institut d'Oncologia) ;
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Rodriguez-Freixinos, Victor (Vall d'Hebron Institut d'Oncologia) ;
Canela, Mercedes (Vall d'Hebron Institut d'Oncologia) ;
Ramon y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Anaplastic Lymphoma Kinase (ALK) positivity represents a novel molecular target in a subset of Non-Small Cell Lung Cancers (NSCLC). We explore Fluorescence in situ Hybridization (FISH) and Immunohistochemistry (IHC) as diagnostic methods for ALK positive patients and to describe its prevalence and outcomes in a population of NSCLC patients. [...]
2013 - 10.1371/journal.pone.0052261
PloS one, Vol. 8 (january 2013)
|
|
|
3.
|
|
6 p, 916.0 KB |
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
/
De Mattos-Arruda, Leticia (Universitat Autònoma de Barcelona) ;
Mayor, Regina (Vall d'Hebron Institut d'Oncologia) ;
Ng, Charlotte K. Y. (Memorial Sloan Kettering Cancer Center) ;
Weigelt, Britta (Memorial Sloan Kettering Cancer Center) ;
Martinez-Ricarte, Fran (Universitat Autònoma de Barcelona) ;
Torrejon, Davis (Vall d'Hebron Institut d'Oncologia) ;
Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Raventós, Carolina (Vall d'Hebron Institut d'Oncologia) ;
Tang, Jiabin (Memorial Sloan Kettering Cancer Center) ;
Guerini-Rocco, Elena (Memorial Sloan Kettering Cancer Center) ;
Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Lois, Sergio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Marín, Oscar (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
de la Cruz, Xavier (Institució Catalana de Recerca i Estudis Avançats) ;
Piscuoglio, Salvatore (Memorial Sloan Kettering Cancer Center) ;
Towers, Russel (Department of Surgery, Memorial Sloan Kettering Cancer Center) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ramón y Cajal, Santiago (Universitat Autònoma de Barcelona) ;
Carles, Joan (Vall d'Hebron Institut d'Oncologia) ;
Rodon, Jordi (Vall d'Hebron Institut d'Oncologia) ;
González-Cao, María (Quirón Dexeus University Hospital) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Felip, Enriqueta (Universitat Autònoma de Barcelona) ;
Sahuquillo Barris, Juan (Universitat Autònoma de Barcelona) ;
Berger, Michael F. (Memorial Sloan Kettering Cancer Center) ;
Cortés, Javier (Universitat Autònoma de Barcelona) ;
Reis-Filho, Jorge S. (Memorial Sloan Kettering Cancer Center) ;
Seoane Suárez, Joan (Universitat Autònoma de Barcelona)
Cell-free circulating tumour DNA (ctDNA) in plasma has been shown to be informative of the genomic alterations present in tumours and has been used to monitor tumour progression and response to treatments. [...]
2015 - 10.1038/ncomms9839
Nature communications, Vol. 6 (november 2015)
|
|
|
4.
|
|
9 p, 1.8 MB |
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
/
Fernandes Neto, João M. (The Netherlands Cancer Institute (NKI) (Netherlands)) ;
Nadal, Ernest (Institut d'Investigació Biomèdica de Bellvitge) ;
Bosdriesz, Evert (Vrije Universiteit) ;
Ooft, Salo N. (The Netherlands Cancer Institute (NKI) (Netherlands)) ;
Farre, Lourdes (Fundação Oswaldo Cruz (Brasil)) ;
McLean, Chelsea (The Netherlands Cancer Institute (NKI) (Netherlands)) ;
Klarenbeek, Sjoerd (The Netherlands Cancer Institute. Experimental Animal Pathology) ;
Jurgens, Anouk (The Netherlands Cancer Institute (NKI) (Netherlands)) ;
Hagen, Hannes (The Netherlands Cancer Institute (NKI) (Netherlands)) ;
Wang, Liqin (The Netherlands Cancer Institute (NKI) (Netherlands)) ;
Felip, Enriqueta (Universitat Autònoma de Barcelona) ;
Martinez-Marti, Alex (Universitat Autònoma de Barcelona) ;
Vidal, August (Institut d'Investigació Biomèdica de Bellvitge) ;
Voest, Emile (The Netherlands Cancer Institute (NKI) (Netherlands)) ;
Wessels, Lodewyk F. A. (The Netherlands Cancer Institute (NKI) (Netherlands)) ;
van Tellingen, Olaf (The Netherlands Cancer Institute (NKI) (Netherlands)) ;
Villanueva, Alejandro (Hospital Universitari de Bellvitge) ;
Bernards, Rene (The Netherlands Cancer Institute (NKI) (Netherlands))
Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. [...]
2020 - 10.1038/s41467-020-16952-9
Nature communications, Vol. 11 (june 2020)
|
|
|
5.
|
|
10 p, 367.0 KB |
ESMO Management and treatment adapted recommendations in the COVID-19 era : Lung cancer
/
Passaro, Antonio (IRCCS European Institute of Oncology (Milà, Itàlia)) ;
Addeo, Alfredo (Geneva University Hospitals (Suïssa)) ;
Von Garnier, Christophe (Centre Hospitalier Universitaire Vaudois) ;
Blackhall, Fiona (University of Manchester) ;
Planchard, David (Gustave Roussy) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Dziadziuszko, Rafal (Gdanski Uniwersytet Medyczny) ;
De Marinis, Filippo (IRCCS European Institute of Oncology (Milà, Itàlia)) ;
Reck, Martin (LungenClinic) ;
Bouchaab, Hasna (Centre Hospitalier Universitaire Vaudois) ;
Peters, Solange (Centre Hospitalier Universitaire Vaudois) ;
Universitat Autònoma de Barcelona
The COVID-19 pandemic, characterised by a fast and global spread during the first months of 2020, has prompted the development of a structured set of recommendations for cancer care management, to maintain the highest possible standards. [...]
2020 - 10.1136/esmoopen-2020-000820
ESMO open, Vol. 5 (january 2020)
|
|
|
6.
|
|
14 p, 572.1 KB |
Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer
/
Frigola Rissech, Joan (Vall d'Hebron Institut d'Oncologia) ;
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Carbonell, Caterina (Vall d'Hebron Institut d'Oncologia) ;
Callejo, Anna (Vall d'Hebron Institut d'Oncologia) ;
Iranzo, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
Pardo, Nuria (Vall d'Hebron Institut d'Oncologia) ;
Saoudi-Gonzalez, Nadia (Vall d'Hebron Institut d'Oncologia) ;
Martinez, Débora (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Jiménez, José (Vall d'Hebron Institut d'Oncologia) ;
Sansano, Irene (Hospital Universitari Vall d'Hebron) ;
Mancuso, Francesco M. (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Montuenga, Luis M. (Instituto de Investigación Sanitaria de Navarra) ;
Sanchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Amat, Ramón (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Immunotherapy has transformed advanced non-small cell lung cancer (NSCLC) treatment strategies and has led to unprecedented long-lasting responses in some patients. However, the molecular determinants driving these long-term responses remain elusive. [...]
2020 - 10.1002/1878-0261.12891
Molecular Oncology, 2020
|
|
|
7.
|
|
13 p, 6.8 MB |
Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity
/
Prat, Aleix (Vall d'Hebron Institut d'Oncologia) ;
Adamo, Barbara (Vall d'Hebron Institut d'Oncologia) ;
Fan, Cheng (Lineberger Comprehensive Cancer Center, University of North Carolina) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Vidal Losada, Maria (Vall d'Hebron Institut d'Oncologia) ;
Galván, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Palmer, Héctor G. ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Dawood, Shaheenah (Department of Medical Oncology, Dubai Hospital) ;
Rodón, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron) ;
Campo, Josep Maria Del (Vall d'Hebron Institut d'Oncologia) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
To improve our understanding of the biological relationships among different types of cancer, we have characterized variation in gene expression patterns in a set of 1,707 samples representing 6 human cancer types (breast, ovarian, brain, colorectal, lung adenocarcinoma and squamous cell lung cancer). [...]
2013 - 10.1038/srep03544
Scientific reports, Vol. 3 (december 2013)
|
|
|
8.
|
|
11 p, 515.9 KB |
Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain
/
Rodríguez-Lescure, A. (Hospital General Universitario de Elche) ;
de la Peña, F. A. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Aranda, E. (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Calvo, A. (Hospital General Universitario Gregorio Marañón) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Garrido, Pilar (Hospital Universitario Ramón y Cajal (Madrid)) ;
Vera, Ruth (Complejo Hospitalario de Navarra) ;
Universitat Autònoma de Barcelona
The Spanish Society of Medical Oncology (SEOM) has carried out a study to analyse the conditions of access to oncology drugs in clinical practice in Spain. For the first time, the access of predictive biomarkers has also been analyzed. [...]
2020 - 10.1007/s12094-020-02366-y
Clinical & Translational Oncology, Vol. 22 (june 2020) , p. 2253-2263
|
|
|
9.
|
|
4 p, 1018.1 KB |
Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation
/
Cedrés, Susana (Hospital Universitari Vall d'Hebron) ;
Felip, Enriqueta (Universitat Autònoma de Barcelona) ;
Cruz, Cristina (Hospital Universitari Vall d'Hebron) ;
Martinez de Castro, Ana (Hospital Universitari Vall d'Hebron) ;
Pardo, Nuria (Universitat Autònoma de Barcelona) ;
Navarro, Alejandro (Universitat Autònoma de Barcelona) ;
Martinez-Marti, Alex (Universitat Autònoma de Barcelona) ;
Remon, Jordin (Vall d'Hebron Institut d'Oncologia) ;
Zeron-Medina, Jorge (Hospital Universitari Vall d'Hebron) ;
Balmaña Gelpí, Judith (Universitat Autònoma de Barcelona) ;
Llop-Guevara, Alba (Experimental Therapeutic Group) ;
Miquel, Josep M. (Vall d'Hebron Institut d'Oncologia) ;
Sansano, Irene (Pathology Department) ;
Nuciforo, Paolo (Molecular Oncology Group) ;
Mancuso, Francesco (Cancer Genomic Group) ;
Serra, Violeta (Experimental Therapeutic Group) ;
Vivancos, Ana (Cancer Genomic Group)
Heat shock proteins (HSPs) are molecular chaperones that maintain proteins in their correct conformation to ensure stability and protect carcinoma cells from apoptosis. HSP90 inhibitors (HSP90i) block multiple targets simultaneously, and despite responses in a selected population, no HSP90i have yet been approved. [...]
2018 - 10.1093/jnci/djy012
Journal of the National Cancer Institute, Vol. 110 (february 2018) , p. 914-917
|
|
|
10.
|
|
13 p, 2.1 MB |
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma : the ROSING Study
/
Conde, Esther (Hospital Universitario HM Sanchinarro (Madrid)) ;
Hernández, Susana (Hospital Universitario HM Sanchinarro (Madrid)) ;
Martinez, Rebeca (Hospital Universitario HM Sanchinarro (Madrid)) ;
Angulo, Bárbara (Hospital Universitario HM Sanchinarro (Madrid)) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Collazo-Lorduy, Ana (Hospital Universitario HM Sanchinarro (Madrid)) ;
Jimenez, Beatriz (Hospital Universitario HM Sanchinarro (Madrid)) ;
Muriel, Alfonso (Hospital Universitario Ramón y Cajal (Madrid)) ;
Mate Sanz, Jose Luís (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Aranda, Ignacio (Instituto de Investigación Sanitaria y Biomédica de Alicante) ;
Massuti, Bartomeu (Instituto de Investigación Sanitaria y Biomédica de Alicante) ;
Rojo, Federico (Centro de Investigación Biomédica en Red de Cáncer) ;
Dómine Gómez, Manuel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Sansano, Irene (Hospital Universitari Vall d'Hebron) ;
Garcia, Felip (Quironsalud Hospital) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Mancheño, Nuria (Hospital Universitari i Politècnic La Fe de València) ;
Juan, Óscar (Hospital Universitari i Politècnic La Fe de València) ;
Sanz, Julián (Hospital Clínico San Carlos (Madrid)) ;
Gonzalez-Larriba, José Luis (Hospital Clínico San Carlos (Madrid)) ;
Atienza-Cuevas, Lidia (Hospital Universitario Puerta del Mar (Cadis, Andalusia)) ;
Arriola-Arellano, Esperanza (Hospital Universitario Puerta del Mar (Cadis, Andalusia)) ;
Abdulkader, Ihab (Clinico de Santiago University Hospital) ;
Garcia-Gonzalez, Jorge (Clinico de Santiago University Hospital) ;
Camacho, Carmen (Insular Materno-Infantil University Hospital Complex) ;
Rodriguez-Abreu, Delvys (Insular Materno-Infantil University Hospital Complex) ;
Teixido, Cristina (Clinic Hospital) ;
Reguart, Noemi (Clinic Hospital) ;
Gonzalez-Piñeiro, Ana (Alvaro Cunqueiro Hospital) ;
Lazaro-Quintela, Martín (Alvaro Cunqueiro Hospital) ;
Lozano, María Dolores (Clínica Universidad de Navarra) ;
Gurpide, Alfonso (Clínica Universidad de Navarra) ;
Gómez-Román, Javier (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Lopez-Brea, M. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Pijuan, Lara (Hospital del Mar (Barcelona, Catalunya)) ;
Salido, Marta (Hospital del Mar (Barcelona, Catalunya)) ;
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ;
Company, Amparo (Clinico University Hospital) ;
Insa, Amelia (Clinico University Hospital) ;
Esteban-Rodriguez, Isabel (Hospital Universitario La Paz (Madrid)) ;
Saiz, Mónica (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Azkona, Eider (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Alvarez, Ramiro (Hospital Universitario Miguel Servet (Saragossa)) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
Plaza, María Luz (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Aguiar de Sousa, Diana (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Enguita, Ana Belén (Hospital Universitario 12 de Octubre (Madrid)) ;
Benito, Amparo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid)) ;
Garrido, Pilar (Centro de Investigación Biomédica en Red de Cáncer) ;
Lopez-Rios, Fernando (Hospital Universitario HM Sanchinarro (Madrid)) ;
Universitat Autònoma de Barcelona
Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. [...]
2019 - 10.1016/j.jtho.2019.07.005
Journal of Thoracic Oncology, Vol. 14 Núm. 12 (december 2019) , p. 2120-2132
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
